Skip to content

Precigen PGEN Net Income

Net Income at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.68B+9.0%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$727.2M-10.1%
Gilead Sciences logo
Gilead SciencesGILD
$2.02B+53.7%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$104.9M-20.7%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-$99.11M-11.0%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
-$74.11M-33.9%

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's net income?
Precigen (PGEN) reported net income of -$7.93M in Q1 2026.
How has Precigen's net income changed year-over-year?
Precigen's net income increased by 85.4% year-over-year, from -$54.15M to -$7.93M.
What is the long-term trend for Precigen's net income?
Over 3 years (2021 to 2025), Precigen's net income has grown at a 39.6% compound annual growth rate (CAGR), from -$92.17M to -$250.64M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.